GeNeuro, a Geneva-based biopharmaceutical company focusing on treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and severe neuropsychiatric consequences of COVID-19 (post-COVID), has successfully completed a €5 million capital increase.     The increase involved a private placement of 4,666,901 new GeNeuro ordinary bearer shares for specialized and strategic … Continue reading Successful € 5 Million Capital Increase for GeNeuro